Cumulative irritation potential of topical retinoid formulations

Journal of Drugs in Dermatology

Volumn 7, Issue 8, 2008, Pages

  Leyden, James J ^a,b   Grossman, Rachel ^c   Nighland, Marge ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b Skin Study Center   (United States)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; DERMATOLOGICAL AGENT; IRRITANT AGENT; NAPHTHALENE DERIVATIVE; RETINOIC ACID;

ACNE VULGARIS; ADULT; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; RANDOMIZED CONTROLLED TRIAL; SKIN; TOPICAL DRUG ADMINISTRATION;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IRRITANTS; NAPHTHALENES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN; TRETINOIN;

EID: 58149109858     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Phillips TJ. An update on the safety and effIcacy of 1. topical Phillips TJ. An update on the safety and effi cacy of topical retinoids. Cutis. 2005;75 (Suppl):14-24.
2. Chivot M. Retinoid therapy for acne. A comparative review. Am J Clin Dermatol. 2005;6:13-19. (Pubitemid 40289257)
3. Bikowski JB. Mechanisms of the comedolytic and anti-infl ammatory properties of topical retinoids. J Drugs Dermatol. 2005;4:41-47.
4. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4:473-492. (Pubitemid 36871766)
5. Webster G. Mechanism-based treatment of acne vulgaris: the value of combination therapy. J Drugs Dermatol. 2005;4:281-288.
6. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol. 2005;174:2467-2470. (Pubitemid 40279655)
7. Del Rosso JQ. The role of the vehicle in combination acne therapy. Cutis. 2005;76 (Suppl):15-18. (Pubitemid 41290889)
8. Embil K, Nacht S. The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13:575-588. (Pubitemid 26283810)
9. Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol. 2006;54:242-250. (Pubitemid 43144393)
10. Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998;139 (Suppl):34-40.
11. Leyden J, Grove G, Zerweck C. Facial tolerability of topical retinoid therapy. J Drugs Dermatol. 2004;3:641-651.
12. Soschin D, Leyden JJ. Sorbic acid-induced erythema and edema. J Am Acad Dermatol. 1986;14:234-241. (Pubitemid 16068072)
13. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tretinoin microsphere 0.04% and 0.1%. Cutis. 2005;75:238-243. (Pubitemid 40627632)